A new program from Optum Rx would offer greater predictability by using a guarantee-based pricing model.
Optum Rx's new Clear Trend Guarantee program is a guarantee-based pricing model that will provide more predictability and transparency for drug prices.
Image credit: adragan - stock.adobe.com
Optum Rx announced a new value-based pricing model with an emphasis on predictability and transparency.1 When the Clear Trend Guarantee program launches January 1, 2025, it will combine guarantees into a single per-member cost.
The new program is a value-based model with shared savings, according to Optum Rx, which is the pharmacy benefit manager (PBM) of UnitedHealthcare. It is a guarantee-based pricing model combining retail, home delivery, specialty drug, and rebate components into a per-member guarantee.
“It is more important now than ever before to be an innovator in health care and to drive affordability and value for plan sponsors and members,” Patrick Conway, MD, CEO of OptumRx, said in a statement. “We are not stopping with Clear Trend Guarantee, and will continue to deliver clear information, transparent and lowest net cost, choice, and a simplified pharmacy benefit for everyone.”1
The Clear Trend Guarantee program is part of Optum Rx’s Cost Made Clear solutions, which includes Cost Clarity, a model that bases costs on independent cost baselines, and Cost Advantage, a pass-through model using average ingredient costs and reflecting real-time network price improvements.2
The announcement is part of a wave of changes from insurers to offer more transparency in drug pricing.3,4 At the end of 2023, CVS Health introduced CostVantage, which sets costs using a formula based on the drug cost, a set markup, and a fee for pharmacy services. TrueCost from CVS offers client pricing reflecting the true net cost of prescription drugs with a transparent look at administrative fees.
Meanwhile, Express Scripts, a subsidiary of Cigna, announced ClearNetwork, a cost-plus pricing model that charges a “straight-forward estimated acquisition cost” and a small markup for pharmacy dispensing and service costs.3,5
These announcements come while PBMs are in the spotlight for their lack of transparency. There have been growing calls for years for PBM reform. At the Community Oncology Alliance Community Oncology Conference, speakers said there are real prospects for PBM reform this year, even with the “lame duck” session after Election Day.6
Congress first turned its attention to PBMs in March 2020, just as everything shut down due to COVID-19, and attention has been on PBMs ever since.7 Senate Finance Committee Chair Ron Wyden (D, Oregon) and Ranking Member Mike Crapo (R, Idaho) have been leading bipartisan efforts to pass PBM reforms to crack down on “their shadowy tactics” that drive up drug costs.8
“Certain pharmacy benefit manager practices continue to jeopardize the viability and financial stability of pharmacies, forcing far too many to close up shop,” Crapo said in a statement.8 “Congress must pass our comprehensive, bipartisan legislation to reduce out-of-pocket medication costs for seniors, enhance federal oversight, and shore up patients’ access to the pharmacy of their choice.”
Bipartisan legislation was first introduced in Congress in 2023. In addition, and in March 2024, Wyden and Crapo renewed their call to pass the legislation. Their legislation has support from pharmacy advocates, including the National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association.
"PBM profits are soaring while they make patients pay more for their medicine and make it impossible for pharmacies of any size to stay open,” said Steven C. Anderson, president and CEO of NACDS.8 “It's time for Congress to pass real PBM reform, particularly for Americans in Medicare and Medicaid. Patients and the pharmacies that serve them can no longer wait. It's time to get this done."
References
1. Optum Rx announces new pricing model to offer clients another transparent, predictable way to manage drug trend. News release. UnitedHealth Group. May 20, 2024. Accessed May 21, 2024. https://www.unitedhealthgroup.com/newsroom/posts/2024/2024-05-optum-rx-clear-trend-guarantee.html
2. New Optum Rx payment solutions continue to empower clients with more choice, transparency in pharmacy benefits. News release. UnitedHealth Group. April 24, 2023. Accessed May 21, 2024. https://www.unitedhealthgroup.com/newsroom/posts/2023/2023-04-24-optum-rx-enhancements-preserving-choice.html
3. Joszt L. CVS announces more transparent model for pharmacy reimbursement, drug costs. AJMC®. December 5, 2023. Accessed May 21, 2024. https://www.ajmc.com/view/cvs-announces-more-transparent-model-for-pharmacy-reimbursement-drug-costs
4. CVS Health highlights path to accelerating long-term growth through building a world of health around every consumer. News release. CVS Health. December 5, 2023. Accessed May 21, 2204. https://www.cvshealth.com/news/company-news/our-path-to-accelerating-long-term-growth.html
5. Express Scripts introduces new option to give clients maximum simplicity in drug pricing. News release. PR Newswire. November 14, 2023. Accessed May 21, 2024. https://www.prnewswire.com/news-releases/express-scripts-introduces-new-option-to-give-clients-maximum-simplicity-in-drug-pricing-301986745.html
6. Caffrey M. Change Healthcare could get Congress’ attention before break for election. AJMC. April 6, 2024. Accessed May 21, 2024. https://www.ajmc.com/view/change-healthcare-could-get-congress-attention-before-break-for-election
7. Caffrey M. Oncology practices keep pace with PBMs, in court and beyond. AJMC. April 5, 2024. Accessed May 21, 2024. https://www.ajmc.com/view/oncology-practices-keep-pace-with-pbms-in-court-and-beyond
8. Wyden, Crapo call for swift passage of bipartisan PBM reforms. News release. US Senate Committee on Finance. March 14, 2024. Accessed May 21, 2024. https://www.finance.senate.gov/chairmans-news/wyden-crapo-call-for-swift-passage-of-bipartisan-pbm-reforms
Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA
August 15th 2025Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.
Read More
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending
August 8th 2025A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.
Read More